advertisement
Abstract #6872 Published in IGR 4-1
A short term study of the additive effect of timolol and brimonidine on intraocular pressure
Arici MK; Sayici M; Toker M; Erdogan H; Topalkara AEye 2002; 16: 39-43
PURPOSE: To evaluate the additive ocular hypotensive effect of the combination of brimonidine and timolol on intraocular pressure (IOP) reduction in patients with glaucoma. METHODS: This was a prospective, randomized, double-masked, crossover study in 20 patients with primary open-angle glaucoma (POAG) on therapy receiving timolol maleate 0.5% twice daily, with IOP greater than or equal to 22 mmHg in one eye. The treatment period was three weeks and, during this period, timolol + brimonidine or timolol + placebo were applied topically twice daily and IOP, blood pressure, heart rate and pupil size were measured. RESULTS: Combined therapy (timolol + brimonidine) had a clinically significant IOP-lowering effect during the treatment period (p < 0.01). The mean diurnal IOP was significantly reduced by an average of 5.1-5.9 mmHg (21.2-24.5%) compared with baseline value. The timolol + placebo combination had no clinically significant IOP-lowering effect (p > 0.05). No clinically significant side-effects were observed during the treatment of both groups. CONCLUSIONS: This study showed that the combination of topically applied brimonidine and timolol cause a marked and sustained IOP reduction.
Dr. M.K. Arici, Department of Ophthalmology, Cumhuriyet University School of Medicine, Sivas, Turkey. kemalarici@hotmail.com
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
